Navigation Links
Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008
Date:7/30/2008

development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and completed the enrollment of its first Phase 3 clinical trial in June 2008. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza, is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated news release and conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inh
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
2. Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
3. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
4. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
5. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
6. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
7. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
8. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
9. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
10. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
11. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... DENVER , Aug. 27, 2014   MSC ... and patient safety, today announced the appointment of ... With 28 years of experience preparing companies ... in 2013 as Executive Vice President of Corporate Development ... healthcare performance improvement business , as well as corporate ...
(Date:8/27/2014)... , Aug. 27, 2014 ... the "Global Lactic Acid  (Biodegradable Polymer, Food ... Trends & Forecasts to 2019" report to ... simplest hydroxyl-carboxylic acid with an asymmetrical carbon atom. ... the biodegradable polymer, food and beverage, personal care ...
(Date:8/27/2014)... , Aug. 27, 2014 Guggenheim Securities, the ... today announced the hiring of veteran equity analyst Charles ... analyst. Mr. Butler will focus on the biotech/biopharma sector. ... a wealth of experience and a broad network of ... Senior Managing Director and Head of Equities at Guggenheim ...
(Date:8/27/2014)... , Aug. 27, 2014 Research and ... Stable Isotope Ratio Mass Spectrometer Industry Report 2014" ... Stable Isotope Ratio Mass Spectrometer Industry Report 2014 is ... of the global isotope ratio mass spectrometer industry. ... industry including definitions, classifications, applications and industry chain structure. ...
Breaking Biology Technology:MSC names Mary Beth Loesch President and CEO 2Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2
... researchers at Arizona State University, have been awarded funding ... producing renewable fuel. This award will permit four ... Jones in the department of chemistry and biochemistry, to ... This will lead to ways of significantly increasing the ...
... 2011 Spherix Incorporated (Nasdaq: SPEX ) ... metabolic syndrome and atherosclerosis and provider of technical and ... companies – today reported financial results for the year ... Upcoming Highlights Pharmaceutical Development ...
... 30, 2011 SuperNova Diagnostics®, Inc., a privately-held ... applications, announced today that it has signed an ... Ltd. ("KSB"), a biotechnology diagnostics company specializing in ... and research reagents in China and affiliated markets ...
Cached Biology Technology:Biological nanowires expedite future fuel production 2Spherix Announces 2010 Financial Results 2Spherix Announces 2010 Financial Results 3Spherix Announces 2010 Financial Results 4Spherix Announces 2010 Financial Results 5Spherix Announces 2010 Financial Results 6Spherix Announces 2010 Financial Results 7SuperNova Diagnostics® Announces Agreement with KSB Diagnostics of China to Commercialise Neopterin Diagnostics 2SuperNova Diagnostics® Announces Agreement with KSB Diagnostics of China to Commercialise Neopterin Diagnostics 3
(Date:8/27/2014)... Aug. 27, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) ... underwritten public offering of units of common stock and ... gross proceeds of $20 million, prior to deducting underwriting ... Company.  The shares and warrants are immediately separable and ... sold in the offering consists of 2,000 shares of ...
(Date:8/27/2014)... Duke University researchers have identified a gene that could ... encodes a protein in the cell membrane of plants ... plant,s water conservation machinery accordingly. , "It,s similar ... of biology at Duke. , The findings, which ... could make it easier to feed the world,s growing ...
(Date:8/27/2014)... the brain of mice, scientists have altered the ... by Howard Hughes Medical Institute investigator Susumu Tonegawa ... that the connections between the part of the ... and the part of the brain that stores ... , Altering those connections can transform a ...
Breaking Biology News(10 mins):WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Water 'thermostat' could help engineer drought-resistant crops 2Researchers change the emotional association of memories 2Researchers change the emotional association of memories 3Researchers change the emotional association of memories 4
... health authorities all over the world are expecting a ... chronic diseases of bone, muscle and joints. The IOF-ESCEO ... become an important educational and research forum to help ... diseases. Held annually in Europe, the Congress is ...
... cells exist in two different states and each state ... an international collaboration of researchers. Their finding sheds new ... disease. "The lethal part of cancer is its ... senior study author Max S. Wicha, M.D., Distinguished Professor ...
... project launches today, investigating the social and political drivers ... largest carbon dioxide emitter by volume, rather than focusing ... change worldwide we need to transform the way we ... population. And nowhere is the approach to innovation across ...
Cached Biology News:New breast cancer stem cell findings explain how cancer spreads 2
... Product Goat polyclonal to Cholesterol ... Reactivity / Specificity Cross-reacts with ... Background Information Cholesterol oxidases exist ... oxidases and are implicated in bacterial pathogenesis. ...
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
Biology Products: